{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:37:35Z","timestamp":1792841855944,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Spinal Cord"],"DOI":"10.1038\/s41393-026-01289-9","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T18:10:11Z","timestamp":1792779011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in gabapentinoid and opioid dispensing in individuals with spinal cord injury: a retrospective cohort study"],"prefix":"10.1038","author":[{"given":"Jaycee R.","family":"Farmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-9218","authenticated-orcid":false,"given":"Vanessa K.","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-1032","authenticated-orcid":false,"given":"Stephan K. W.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L. K.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1289_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/S40265-022-01810-3","volume":"83","author":"CD Williams","year":"2023","unstructured":"Williams CD, Al-Jammali Z, Herink MC. Gabapentinoids for pain: a review of published comparative effectiveness trials and data submitted to the FDA for approval. Drugs. 2023;83:37\u201353. https:\/\/doi.org\/10.1007\/S40265-022-01810-3","journal-title":"Drugs"},{"key":"1289_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/JAMA.2017.21897","volume":"319","author":"JD Wallach","year":"2018","unstructured":"Wallach JD, Ross JS. Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts. JAMA. 2018;319:776\u20138. https:\/\/doi.org\/10.1001\/JAMA.2017.21897","journal-title":"JAMA"},{"key":"1289_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","volume":"179","author":"CW Goodman","year":"2019","unstructured":"Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med. 2019;179:695\u2013701. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0086","journal-title":"JAMA Intern Med"},{"key":"1289_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41467-023-40637-8","volume":"14","author":"AYL Chan","year":"2023","unstructured":"Chan AYL, Yuen ASC, Tsai DHT, Lau WCY, Jani YH, Hsia Y, et al. Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study. Nat Commun. 2023;14:1\u201311. https:\/\/doi.org\/10.1038\/S41467-023-40637-8","journal-title":"Nat Commun"},{"key":"1289_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/S40265-023-01903-7","volume":"83","author":"E Widerstr\u00f6m-Noga","year":"2023","unstructured":"Widerstr\u00f6m-Noga E. Neuropathic pain and spinal cord injury: management, phenotypes, and biomarkers. Drugs. 2023;83:1001\u201325. https:\/\/doi.org\/10.1007\/S40265-023-01903-7","journal-title":"Drugs"},{"key":"1289_CR6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1080\/10790268.2023.2228584","volume":"47","author":"A Yadav","year":"2024","unstructured":"Yadav A, Joshi M. Occurrence of neuropathic pain and its characteristics in patients with traumatic spinal cord injury. J Spinal Cord Med. 2024;47:952\u20139. https:\/\/doi.org\/10.1080\/10790268.2023.2228584","journal-title":"J Spinal Cord Med"},{"key":"1289_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/EJP.905","volume":"21","author":"D Burke","year":"2017","unstructured":"Burke D, Fullen BM, Stokes D, Lennon O. Neuropathic pain prevalence following spinal cord injury: a systematic review and meta-analysis. Eur J Pain. 2017;21:29\u201344. https:\/\/doi.org\/10.1002\/EJP.905","journal-title":"Eur J Pain"},{"key":"1289_CR8","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1089\/NEU.2018.5960","volume":"36","author":"FM Warner","year":"2019","unstructured":"Warner FM, Cragg JJ, Jutzeler CR, Finnerup NB, Werhagen L, Weidner N, et al. Progression of neuropathic pain after acute spinal cord injury: a meta-analysis and framework for clinical trials. J Neurotrauma. 2019;36:1461\u20138. https:\/\/doi.org\/10.1089\/NEU.2018.5960","journal-title":"J Neurotrauma"},{"key":"1289_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.apmr.2010.07.241","volume":"92","author":"GG Whiteneck","year":"2011","unstructured":"Whiteneck GG, Gassaway J, Dijkers MP, Lammertse DP, Hammond F, Heinemann AW, et al. Inpatient and postdischarge rehabilitation services provided in the first year after spinal cord injury: findings from the SCIRehab study. Arch Phys Med Rehabil. 2011;92:361\u20138. https:\/\/doi.org\/10.1016\/j.apmr.2010.07.241","journal-title":"Arch Phys Med Rehabil"},{"key":"1289_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41393-021-00744-z","volume":"60","author":"E Loh","year":"2022","unstructured":"Loh E, Mirkowski M, Agudelo AR, Allison DJ, Benton B, Bryce TN, et al. The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord injury: 2021 update. Spinal Cord. 2022;60:548\u201366. https:\/\/doi.org\/10.1038\/s41393-021-00744-z","journal-title":"Spinal Cord"},{"key":"1289_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/10790268.2021.1969503","volume":"46","author":"Q Guan","year":"2023","unstructured":"Guan Q, Calzavara A, Cadel L, Hogan ME, McCormack D, Patel T, et al. Indicators of publicly funded prescription opioid use among persons with traumatic spinal cord injury in Ontario, Canada. J Spinal Cord Med. 2023;46:881\u20138. https:\/\/doi.org\/10.1080\/10790268.2021.1969503","journal-title":"J Spinal Cord Med"},{"key":"1289_CR12","doi-asserted-by":"publisher","first-page":"e1002396.","DOI":"10.1371\/JOURNAL.PMED.1002396","volume":"14","author":"T Gomes","year":"2017","unstructured":"Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case\u2013control study. PLoS Med. 2017;14:e1002396. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1002396","journal-title":"PLoS Med"},{"key":"1289_CR13","doi-asserted-by":"publisher","first-page":"e2031647.","DOI":"10.1001\/jamanetworkopen.2020.31647","volume":"3","author":"K Bykov","year":"2020","unstructured":"Bykov K, Bateman BT, Franklin JM, Vine SM, Patorno E. Association of gabapentinoids with the risk of opioid-related adverse events in surgical patients in the United States. JAMA Netw Open. 2020;3:e2031647. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.31647","journal-title":"JAMA Netw Open"},{"key":"1289_CR14","doi-asserted-by":"publisher","first-page":"1009950.","DOI":"10.3389\/FPHAR.2022.1009950","volume":"13","author":"J Hahn","year":"2022","unstructured":"Hahn J, Jo Y, Yoo SH, Shin J, Yu YM, Ah YM. Risk of major adverse events associated with gabapentinoid and opioid combination therapy: a systematic review and meta-analysis. Front Pharmacol. 2022;13:1009950. https:\/\/doi.org\/10.3389\/FPHAR.2022.1009950","journal-title":"Front Pharmacol"},{"key":"1289_CR15","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1097\/J.PAIN.0000000000003239","volume":"165","author":"S Muller","year":"2024","unstructured":"Muller S, Bailey J, Bajpai R, Helliwell T, Harrisson SA, Whittle R, et al. Risk of adverse outcomes during gabapentinoid therapy and factors associated with increased risk in UK primary care using the clinical practice research datalink: a cohort study. Pain. 2024;165:2282\u201390. https:\/\/doi.org\/10.1097\/J.PAIN.0000000000003239","journal-title":"Pain"},{"key":"1289_CR16","doi-asserted-by":"publisher","first-page":"116.","DOI":"10.46292\/SCI2602-116","volume":"26","author":"MRL Reyes","year":"2020","unstructured":"Reyes MRL, Elmo MJ, Menachem B, Granda SM. A primary care provider\u2019s guide to managing respiratory health in subacute and chronic spinal cord injury. Top Spinal Cord Inj Rehabil. 2020;26:116. https:\/\/doi.org\/10.46292\/SCI2602-116","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"1289_CR17","doi-asserted-by":"publisher","first-page":"123.","DOI":"10.46292\/SCI2602-123","volume":"26","author":"A Krassioukov","year":"2020","unstructured":"Krassioukov A, Stillman M, Beck LA. A primary care provider\u2019s guide to autonomic dysfunction following spinal cord injury. Top Spinal Cord Inj Rehabil. 2020;26:123. https:\/\/doi.org\/10.46292\/SCI2602-123","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"1289_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1179\/2045772314Y.0000000235","volume":"40","author":"P Kitzman","year":"2017","unstructured":"Kitzman P, Cecil D, Kolpek JH. The risks of polypharmacy following spinal cord injury. J Spinal Cord Med. 2017;40:147\u201353. https:\/\/doi.org\/10.1179\/2045772314Y.0000000235","journal-title":"J Spinal Cord Med"},{"key":"1289_CR19","doi-asserted-by":"publisher","first-page":"232.","DOI":"10.46292\/SCI20-00016","volume":"26","author":"VK Noonan","year":"2021","unstructured":"Noonan VK, Jaglal SB, Humphreys S, Cronin S, Waheed Z, Fallah N, et al. Linking spinal cord injury data sets to describe the patient journey following injury: a protocol. Top Spinal Cord Inj Rehabil. 2021;26:232. https:\/\/doi.org\/10.46292\/SCI20-00016","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"1289_CR20","unstructured":"Population Data BC. Available from: https:\/\/www.popdata.bc.ca\/. Accessed March 2, 2026."},{"key":"1289_CR21","unstructured":"Canadian Institutes for Health Information. Discharge abstract database (hospital separations) data set: V2 2019. Available from: https:\/\/www.popdata.bc.ca\/data\/health\/dad. Accessed March 2, 2026."},{"key":"1289_CR22","unstructured":"BC Ministry of Health. Vital events and statistics deaths data set: V2 2019. Available from: https:\/\/www.popdata.bc.ca\/data\/demographic\/vs_deaths. Accessed March 2, 2026."},{"key":"1289_CR23","unstructured":"Provincial Health Services Authority. BC trauma registry. Available from: https:\/\/www.phsa.ca\/health-professionals\/clinical-resources\/trauma\/bc-trauma-registry. Accessed March 2, 2026."},{"key":"1289_CR24","unstructured":"BC Ministry of Health. Medical services plan data set: V2 2019. Available from: https:\/\/www.popdata.bc.ca\/data\/health\/msp. Accessed March 2, 2026."},{"key":"1289_CR25","unstructured":"BC Ministry of Health. Central demographics file (MSP registration and premium billings, client roster and census geodata)\/consolidation file (MSP registration and premium billing) data set: V2 2019. Available from: https:\/\/www.popdata.bc.ca\/data\/demographic\/consolidation_file. Accessed March 2, 2026."},{"key":"1289_CR26","unstructured":"Canadian Institutes for Health Information. National ambulatory care reporting system data set: V2 2019. Available from: https:\/\/www.popdata.bc.ca\/data\/health\/nacrs. Accessed March 2, 2026."},{"key":"1289_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/sc.2011.109","volume":"50","author":"VK Noonan","year":"2012","unstructured":"Noonan VK, Kwon BK, Soril L, Fehlings MG, Hurlbert RJ, Townson A, et al. The Rick Hansen Spinal Cord Injury Registry (RHSCIR): a national patient-registry. Spinal Cord. 2012;50:22\u20137. https:\/\/doi.org\/10.1038\/sc.2011.109","journal-title":"Spinal Cord"},{"key":"1289_CR28","unstructured":"BC Ministry of Health. PharmaNet data set: V2 2019. Available from: https:\/\/www.popdata.bc.ca\/data\/health\/pharmanet. Accessed March 2, 2026."},{"key":"1289_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"key":"1289_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46292\/SCI2702-1","volume":"27","author":"R Rupp","year":"2021","unstructured":"Rupp R, Biering-S\u00f8rensen F, Burns SP, Graves DE, Guest J, Jones L, et al. International standards for neurological classification of spinal cord injury: revised 2019. Top Spinal Cord Inj Rehabil. 2021;27:1\u201322. https:\/\/doi.org\/10.46292\/SCI2702-1","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"1289_CR31","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/S41393-018-0174-Z","volume":"56","author":"SJT Guilcher","year":"2018","unstructured":"Guilcher SJT, Hogan ME, Calzavara A, Hitzig SL, Patel T, Packer T, et al. Prescription drug claims following a traumatic spinal cord injury for older adults: a retrospective population-based study in Ontario, Canada. Spinal Cord. 2018;56:1059\u201368. https:\/\/doi.org\/10.1038\/S41393-018-0174-Z","journal-title":"Spinal Cord"},{"key":"1289_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.apmr.2021.06.022","volume":"103","author":"ER Felix","year":"2022","unstructured":"Felix ER, Cardenas DD, Bryce TN, Charlifue S, Lee TK, MacIntyre B, et al. Prevalence and impact of neuropathic and nonneuropathic pain in chronic spinal cord injury. Arch Phys Med Rehabil. 2022;103:729\u201337. https:\/\/doi.org\/10.1016\/j.apmr.2021.06.022","journal-title":"Arch Phys Med Rehabil"},{"key":"1289_CR33","doi-asserted-by":"publisher","first-page":"e2300008","DOI":"10.1200\/GO.23.00008.","volume":"9","author":"W Fuentes Pay\u00e1n","year":"2023","unstructured":"Fuentes Pay\u00e1n W, Gonz\u00e1lez Lorenzo K, Gelabert Mart\u00ednez F, Conte Schmidt N, Tortolero-Luna G, Ramos-Fern\u00e1ndez MR, et al. Association between concurrent use of benzodiazepines and opioids and health care utilization among patients with cancer in Puerto Rico. JCO Glob Oncol. 2023;9:e2300008. https:\/\/doi.org\/10.1200\/GO.23.00008","journal-title":"JCO Glob Oncol"},{"key":"1289_CR34","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1080\/10826084.2017.1298617","volume":"52","author":"EA Ferries","year":"2017","unstructured":"Ferries EA, Gilson AM, Aparasu RR, Chen H, Johnson ML, Fleming ML. The prevalence of and factors associated with receiving concurrent controlled substance prescriptions. Subst Use Misuse. 2017;52:1639\u201345. https:\/\/doi.org\/10.1080\/10826084.2017.1298617","journal-title":"Subst Use Misuse"},{"key":"1289_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/10790268.2002.11753609","volume":"25","author":"Q Tai","year":"2002","unstructured":"Tai Q, Kirshblum S, Chen B, Millis S, Johnston M, DeLisa JA. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 2002;25:100\u20135. https:\/\/doi.org\/10.1080\/10790268.2002.11753609","journal-title":"J Spinal Cord Med"},{"key":"1289_CR36","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/J.APMR.2007.07.038","volume":"88","author":"DH Rintala","year":"2007","unstructured":"Rintala DH, Holmes SA, Courtade D, Fiess RN, Tastard LV, Loubser PG. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil. 2007;88:1547\u201360. https:\/\/doi.org\/10.1016\/J.APMR.2007.07.038","journal-title":"Arch Phys Med Rehabil"},{"key":"1289_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/01.brs.0000112068.16108.3a","volume":"29","author":"F Levendoglu","year":"2004","unstructured":"Levendoglu F, Og\u00fcn CO, Ozerbil O, Og\u00fcn TC, Ugurlu H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine. 2004;29:743\u201351. https:\/\/doi.org\/10.1097\/01.brs.0000112068.16108.3a","journal-title":"Spine"},{"key":"1289_CR38","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1212\/01.WNL.0000244422.45278.FF","volume":"67","author":"PJ Siddall","year":"2006","unstructured":"Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2006;67:1792\u2013800. https:\/\/doi.org\/10.1212\/01.WNL.0000244422.45278.FF","journal-title":"Neurology"},{"key":"1289_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1212\/WNL.0b013e318281546b","volume":"80","author":"DD Cardenas","year":"2013","unstructured":"Cardenas DD, Nieshoff EC, Suda K, Goto S, Sanin L, Kaneko T, et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology. 2013;80:533\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e318281546b","journal-title":"Neurology"},{"key":"1289_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/J.PAIN.2007.06.033","volume":"136","author":"JH Vranken","year":"2008","unstructured":"Vranken JH, Dijkgraaf MGW, Kruis MR, van der Vegt MH, Hollmann MW, Heesen M. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008;136:150\u20137. https:\/\/doi.org\/10.1016\/J.PAIN.2007.06.033","journal-title":"Pain"},{"key":"1289_CR41","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1038\/sc.2016.90","volume":"54","author":"SD Guy","year":"2016","unstructured":"Guy SD, Mehta S, Casalino A, C\u00f4t\u00e9 I, Kras-Dupuis A, Moulin DE, et al. The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord: recommendations for treatment. Spinal Cord. 2016;54:S14\u201323. https:\/\/doi.org\/10.1038\/sc.2016.90","journal-title":"Spinal Cord"},{"key":"1289_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/AJP.0000000000000523","volume":"34","author":"LMA B\u00e9langer","year":"2018","unstructured":"B\u00e9langer LMA, Umedaly HS, Noonan VK, Park SE, Prince J, Thorogood NP, et al. Evaluation of a clinical protocol to assess and diagnose neuropathic pain during acute hospital admission. Clin J Pain. 2018;34:104\u201312. https:\/\/doi.org\/10.1097\/AJP.0000000000000523","journal-title":"Clin J Pain"},{"key":"1289_CR43","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jpain.2022.01.006","volume":"23","author":"LR Gorfinkel","year":"2022","unstructured":"Gorfinkel LR, Hasin D, Saxon AJ, Wall M, Martins SS, Cerd\u00e1 M, et al. Trends in prescriptions for non-opioid pain medications among U.S. adults with moderate or severe pain, 2014-2018. J Pain. 2022;23:1187\u201395. https:\/\/doi.org\/10.1016\/j.jpain.2022.01.006","journal-title":"J Pain"},{"key":"1289_CR44","doi-asserted-by":"publisher","first-page":"105022.","DOI":"10.1016\/j.drugpo.2025.105022","volume":"145","author":"H Dasari","year":"2025","unstructured":"Dasari H, Artenie A, Bruneau J, Larney S. Trends in accidental drug overdose mortality in Canada: an analysis from 1974 to 2023. Int J Drug Policy. 2025;145:105022. https:\/\/doi.org\/10.1016\/j.drugpo.2025.105022","journal-title":"Int J Drug Policy"},{"key":"1289_CR45","doi-asserted-by":"publisher","first-page":"107608.","DOI":"10.1016\/J.DRUGALCDEP.2019.107608","volume":"205","author":"S Graupensperger","year":"2019","unstructured":"Graupensperger S, Corey JJ, Turrisi RJ, Evans MB. Individuals with spinal cord injury have greater odds of substance use disorders than non-sci comparisons. Drug Alcohol Depend. 2019;205:107608. https:\/\/doi.org\/10.1016\/J.DRUGALCDEP.2019.107608","journal-title":"Drug Alcohol Depend"},{"key":"1289_CR46","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/add.13324","volume":"111","author":"RV Smith","year":"2016","unstructured":"Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111:1160\u201374. https:\/\/doi.org\/10.1111\/add.13324","journal-title":"Addiction"},{"key":"1289_CR47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/S40265-020-01432-7","volume":"81","author":"KE Evoy","year":"2021","unstructured":"Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021;81:125\u201356. https:\/\/doi.org\/10.1007\/S40265-020-01432-7","journal-title":"Drugs"},{"key":"1289_CR48","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016. JAMA. 2016;315:1624\u201345. https:\/\/doi.org\/10.1001\/jama.2016.1464","journal-title":"JAMA"},{"key":"1289_CR49","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/J.EXPNEUROL.2013.03.008","volume":"247","author":"SA Woller","year":"2013","unstructured":"Woller SA, Hook MA. Opioid administration following spinal cord injury: implications for pain and locomotor recovery. Exp Neurol. 2013;247:328\u201341. https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2013.03.008","journal-title":"Exp Neurol"},{"key":"1289_CR50","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/J.AMEPRE.2021.08.024","volume":"62","author":"C Chen","year":"2022","unstructured":"Chen C, Lo-Ciganic WH, Winterstein AG, Tighe P, Wei YJJ. Concurrent use of prescription opioids and gabapentinoids in older adults. Am J Prev Med. 2022;62:519\u201328. https:\/\/doi.org\/10.1016\/J.AMEPRE.2021.08.024","journal-title":"Am J Prev Med"},{"key":"1289_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00000539-200007000-00035","volume":"91","author":"K Eckhardt","year":"2000","unstructured":"Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg. 2000;91:185\u201391. https:\/\/doi.org\/10.1097\/00000539-200007000-00035","journal-title":"Anesth Analg"},{"key":"1289_CR52","unstructured":"FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) | FDA n.d. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin. Accessed December 18, 2025."},{"key":"1289_CR53","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0304-3959(02)00452-9","volume":"103","author":"PJ Siddall","year":"2003","unstructured":"Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain. 2003;103:249\u201357. https:\/\/doi.org\/10.1016\/S0304-3959(02)00452-9","journal-title":"Pain"}],"container-title":["Spinal Cord"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41393-026-01289-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41393-026-01289-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41393-026-01289-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:07Z","timestamp":1792839727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41393-026-01289-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":53,"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1038\/s41393-026-01289-9","relation":{},"ISSN":["1362-4393","1476-5624"],"issn-type":[{"value":"1362-4393","type":"print"},{"value":"1476-5624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.\u00a0Dr. Stephan K. W. Schwarz is the Editor-in-Chief of the Canadian Journal of Anesthesia\/Journal canadien d\u2019anesth\u00e9sie; he has no financial relationships with commercial entities.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations, including the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2) (\n                      \n                      ). The study was approved by the Clinical Research Ethics Board of The University of British Columbia (Vancouver, BC, Canada; H22-02696-A009). The requirement for informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}